Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recursion Pharmaceuticals Inc.

www.recursionpharma.com

Latest From Recursion Pharmaceuticals Inc.

Finance Watch: High Value Of Exits Keep Biopharma VC Deals At Near-Record Levels

Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.

Financing Deals

Tech Transfer Roundup: GE Healthcare, Vanderbilt Partner To Optimize Precision Cancer Immunotherapy

Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.

Deals Commercial

With First IND, Recursion Readies Its AI, Experimental Biology Approach For The Clinic

Emerging Company Profile: With an early focus on rare, monogenic diseases, Recursion believes its platform combining artificial intelligence and experimental biology can be applied to any disease that can be modeled on a cellular level.

StartUps and SMEs Rare Diseases

Appointments: Basliea, BenevolentAI, OMEICOS, Recursion, Takeda UK And Bone Therapeutics Announce New Hires

New appointments have been announced this week by Basilea, BenevolentAI, OMEICOS Therapeutics, Pharnext, Recursion Pharmaceuticals, Sonde Health, Takeda UK, Bone Therapeutics and Glythera.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Digital Health
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Dermatology
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Recursion Pharmaceuticals Inc.
  • Senior Management
  • Chris C Gibson, PhD, CEO
    Sharath Hegde, PhD, CSO
    Matthew Kinn, VP, Bus. Dev. & Corp. Initiatives
    Tina Larson, COO
  • Contact Info
  • Recursion Pharmaceuticals Inc.
    Phone: (385) 269-0203
    41S Rio Grande St.
    Salt Lake City, UT 84101
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register